Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback